MLN8054 (MLN-8054, CAS: 869363-13-3) is a small molecule inhibitor of Aurora kinase A, which is an enzyme involved in the regulation of cell division. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors.
Chemical name: N-(4-((2-amino-6-chloropyridin-3-yl)methylamino)-2-methoxyphenyl)-4-((4-methylpiperazin-1-yl)methyl)-1H-pyrazole-3-carboxamide
Molecular formula: C24H28ClN9O2
Formula weight: 503.99 g/mol
CAS No: 869363-13-3
Top ten keywords from Google:
Synonyms:
Health benefits of this product: MLN8054 has demonstrated potential health benefits in the area of cancer research, particularly in the treatment of solid tumors. Its primary mode of action is through inhibition of Aurora kinase A, leading to disrupted mitotic spindle formation and subsequent cell division.
Potential effects: MLN8054 has demonstrated efficacy in several preclinical and clinical studies in inhibiting the activity of Aurora kinase A, leading to disrupted mitotic spindle formation and subsequent cell division. It also has potential benefits for inducing apoptosis (programmed cell death), reducing angiogenesis (the formation of new blood vessels that can support tumor growth), and enhancing the immune response to cancer cells. MLN8054 works by disrupting various cellular processes that are necessary for cancer cell survival and growth.
Product mechanism: MLN8054 works by inhibiting the activity of Aurora kinase A, which is an enzyme involved in the regulation of cell division. By inhibiting Aurora kinase A, MLN8054 can disrupt mitotic spindle formation and subsequent cell division, leading to reduced tumor growth and increased apoptosis.
Safety: MLN8054 has been evaluated in several preclinical and clinical trials involving hundreds of participants and has been generally well-tolerated. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as hematological abnormalities (e.g., decreased white blood cell or platelet counts) and hepatic dysfunction. Patients with liver or kidney disease should exercise caution when taking MLN8054, as it may affect these conditions. Pregnant or breastfeeding women should avoid using MLN8054, as its safety in these populations has not been established.
Side effects: Less common but more severe side effects of MLN8054 may include bleeding disorders, cardiovascular events, and liver or kidney dysfunction, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of MLN8054 may vary depending on the patient's condition and treatment goals. In preclinical studies, doses ranging from 10 to 200 mg have been evaluated for various types of cancer. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: MLN8054 (MLN-8054, CAS: 869363-13-3) is a small molecule inhibitor of Aurora kinase A, which is an enzyme involved in the regulation of cell division. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors. Although it has been generally well-tolerated in preclinical and clinical trials, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient populations and cancer types. MLN8054 offers a promising avenue for treatment of cancer by disrupting mitotic spindle formation and inhibiting tumor growth
